NCT02833389 is a Phase 1 clinical trial of UTTR1147A in Neuropathic Diabetic Foot Ulcers, sponsored by Genentech, Inc..

Who is sponsoring NCT02833389?

NCT02833389 is sponsored by Genentech, Inc..

What drugs are being tested in NCT02833389?

Interventions in NCT02833389: Placebo, UTTR1147A.

What condition does NCT02833389 study?

NCT02833389 studies Neuropathic Diabetic Foot Ulcers.

Is NCT02833389 still recruiting?

NCT02833389 is currently completed. Last updated 21 November 2018.

Last reviewed 2018-11-21 · How we verify

NCT02833389

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

Completed Phase 1 Last updated 21 November 2018

What this trial tests

Phase 1 trial testing Placebo in Neuropathic Diabetic Foot Ulcers in 72 participants. Completed in 12 November 2018.

Timeline

14 November 2016

Primary endpoint
12 November 2018

12 November 2018

Quick facts

Lead sponsor	Genentech, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	72
Start date	14 November 2016
Primary completion	12 November 2018
Estimated completion	12 November 2018
Sites	32 locations across Denmark, Italy, United Kingdom, Hungary, United States, Spain

Drugs / interventions tested

Placebo
UTTR1147A — full drug profile →

Conditions studied

Neuropathic Diabetic Foot Ulcers — all drugs for Neuropathic Diabetic Foot Ulcers →

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Neuropathic Diabetic Foot Ulcers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeat dosing of UTTR1147A in participants with neuropathic diabetic foot ulcers that do not respond adequately to standard wound care. Participants across multiple sites will be assigned to one of five cohorts (Cohort A, B, C, D, and E) based on the eligibility criteria and randomized to receive subcutaneous (SC) injections of either UTTR1147A or placebo over 12 weeks in addition to standard wound care.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Chronic Diabetic Wounds and Their Treatment with Skin Substitutes.
Holl J, Kowalewski C, Zimek Z, Fiedor P, et al · · 2021 · cited 205× · PMID 33804192 · DOI 10.3390/cells10030655
The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.
Kragstrup TW, Andersen T, Heftdal LD, Hvid M, et al · · 2018 · cited 53× · PMID 30319661 · DOI 10.3389/fimmu.2018.02226
IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans.
Mar JS, Ota N, Pokorzynski ND, Peng Y, et al · · 2023 · cited 45× · PMID 36894983 · DOI 10.1186/s40168-023-01486-1
The Role of T Helper 22 Cells in Dermatological Disorders.
Pan Y, Du D, Wang L, Wang X, et al · · 2022 · cited 12× · PMID 35911703 · DOI 10.3389/fimmu.2022.911546

Verify or expand the search:

Other trials of UTTR1147A

Trials testing the same drug.

NCT04386616 — A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pne · Phase 2 · completed
NCT03650413 — An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Sever · Phase 2 · terminated
NCT03558152 — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab i · Phase 2 · completed
NCT02749630 — A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis · Phase 1 · completed

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02833389 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 21 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02833389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing